Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

US GSK Clinical Trials Call Center 877-379-3718
GSKClinicalSupportHD@gsk.com


EU GSK Clinical Trials Call Center +44 (0) 20 89904466
GSKClinicalSupportHD@gsk.com


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants and Healthy Chinese and Japanese Participants
Back

A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants and Healthy Chinese and Japanese Participants

Recruiting

Open to: ALL

Age: 18.0 - 65.0

Cambridge

Medical Conditions

Lupus Erythematosus, Systemic

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


This study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of GSK4527363 in healthy participants (Part A), participants with active SLE (Part B), and healthy participants of Chinese and Japanese descent (Part C).

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Sep 2024 May 2027

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : GSK4527363 will be administered to participants.

Intervention Arm Group : Part A: Healthy participants receiving GSK4527363;Part B: Participants with SLE receiving GSK4527363;Part C: Healthy Chinese participants receiving GSK4527363;Part C: Healthy Japanese participants receiving GSK4527363;

Intervention Type : DRUG
Intervention Description : Placebo matching GSK4527363 will be administered to participants.

Intervention Arm Group : Part A: Healthy participants receiving placebo matching GSK4527363;Part C: Healthy Chinese participants receiving placebo matching GSK4527363;Part C: Healthy Japanese participants receiving placebo matching GSK4527363;

Intervention Type : DRUG
Intervention Description : Belimumab will be administered to participants.

Intervention Arm Group : Part A: Healthy participants receiving belimumab;Part B: Participants with SLE receiving belimumab;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • GSK Investigational Site
    Cambridge
    CB2 0GG

EU GSK Clinical Trials Call Center +44 (0) 20 89904466
GSKClinicalSupportHD@gsk.com


US GSK Clinical Trials Call Center 877-379-3718
GSKClinicalSupportHD@gsk.com



The study is sponsored by GlaxoSmithKline



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT06576271
Last updated 14 April 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top